A chimeric antigen receptor (CAR), including an antigen-binding domain, a CD8 or CD28 hinge domain, a DAP10 cytoplasmic domain, a 2B4 cytoplasmic domain, and a CD3z cytoplasmic domain, where the CAR is expressed in natural killer (NK) cells. A method for treating cancer, including administering a therapeutically effective amount of a composition containing a NK cell that expresses the CAR, or a therapeutically effective amount of a cellular therapeutic agent containing a NK cell that expresses the CAR, to a subject in need thereof.

A pharmaceutical product comprising (a) a conjugation product of TNF and a tumour- or tumour vasculature-targeting peptide comprising an NGR, DGR, isoDGR or RGD motif; and (b) a cell comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-specific targeting domain which targets a tumour antigen.

The present invention relates to at least one glycosylation inhibitor for use in combination with CAR cell therapy. Preferably the glycosylation inhibitor improves the therapeutic potential of the CAR cell therapy. The invention also relates to pharmaceutical composition and to population or subpopulation of CAR cell that has been contacted with at least one glycosylation inhibitor.

An isolated polynucleotide comprising the element of: a promoter element that drives expression of the CC motif ligand 5 (a CCL5 promoter) operatively linked to a polynucleotide encoding a fusion polypeptide comprising the Fc and hinge regions of a human IgG CD44 variant 6 (CD44v6) polypeptide is described.

The present disclosure relates to anti-glyco-CD44 antibodies and antigen-binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of CD44 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

Provided is a polymer compound comprising: a hydrophobic moiety binding to natural killer (NK) cells; a cancer cell recognition moiety; and a linker, wherein the hydrophobic moiety is bound to one end of the linker and the cancer cell recognition moiety is bound to the other end of the linker and recognizes NK cells and cancer cells, wherein the cancer cell recognition moiety comprises hyaluronic acid.